Session Information
-
WCLC 2021
2021 World Conference on Lung Cancer
Presentation Date(s):- September 8 - 14, 2021
- Total Presentations: 1107
All times listed are in Mountain Time MDT (UTC-6:00)
PL - Plenary
ES - Education Session
OA - Oral Session
MA - Mini Oral Session
FP - Featured Posters
P - Posters
WS - Workshops
IS - Industry Symposium
MTE - Meet the Expert
BEDG - Brain Exchange Discussion Groups
September 8 Wed
Sep 8 Thursday
September 9 Thu
Sep 9 Friday
September 10 Fri
Sep 10 Saturday
September 11 Sat
Sep 11 Sunday
September 12 Sun
Sep 12 Monday
September 13 Mon
Sep 13 Tuesday
September 14 Tue
Sep 14
-
+
IS01 - Industry Symposium Sponsored by Mirati Therapeutics: Rapid Progress During a Pandemic: Emerging Therapeutic Options for NSCLC
- 12:00 - 13:00
- 9/08/2021
- Location: Industry Symposium Auditorium via Industry Hub
- Not for CME Credit
- Type: Industry Supported Symposium
- Track: N.A.
-
+
IS01.01 - Welcome and Introduction
12:00 - 12:05 | Presenter: Pasi A. Janne
- Abstract
No abstract available for this presentation
-
+
IS01.04 - Advances In NSCLC: Targeted Therapies, Including Targeting KRAS-Driven NSCLC
12:35 - 12:50 | Presenter: Pasi A. Janne
- Abstract
No abstract available for this presentation
-
+
FP09 - Novel Therapeutics and Targeted Therapies
- 00:00 - 00:00
- 9/08/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters (Featured)
- Track: Novel Therapeutics and Targeted Therapies
-
+
FP09.01 - Mobocertinib in Platinum-Pretreated EGFR Exon 20 Insertion+ Metastatic NSCLC Patients With/Without Prior Anti-PD(L)-1 Therapy
00:00 - 00:00 | Presenter: Pasi A. Janne
- Abstract
Loading... -
+
FP09.02 - Mobocertinib (TAK-788) in EGFR Exon 20 Insertion+ Metastatic NSCLC: Patient-Reported Outcomes From EXCLAIM Extension Cohort
00:00 - 00:00 | Presenter: Maria Rosario García Campelo
- Abstract
Loading...
-
+
OA15 - Upcoming Molecular Targeted Agents for EGFR exon 20 Insertion and MET Skipping Mutation
- 18:45 - 19:45
- 9/12/2021
- Location: Program Auditorium
- IASLC CME Accredited
- Type: Oral
- Track: Novel Therapeutics and Targeted Therapies
- Moderators:Helena A Yu
-
+
OA15.01 - Mobocertinib in EGFR Exon 20 Insertion–Positive Metastatic NSCLC Patients With Disease Control on Prior EGFR TKI Therapy
18:45 - 18:55 | Presenter: Alexander Spira
- Abstract
Loading... -
+
OA15.02 - Phase 1 Studies of DZD9008, an Oral Selective EGFR/HER2 Inhibitor in Advanced NSCLC with EGFR Exon20 Insertion Mutations
18:55 - 19:05 | Presenter: Pasi A. Janne
- Abstract
Loading... -
+
OA15.03 - Amivantamab in Non-small Cell Lung Cancer (NSCLC) with MET Exon 14 Skipping (METex14) Mutation: Initial Results from CHRYSALIS
19:05 - 19:15 | Presenter: Alexander Spira
- Abstract
Loading...
